RECEIVED
CENTRAL FAX CENTER
JUL 12 2006

QA0267B - CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
KATERINA LEFTHERIS, ET AL.

ART UNIT: **1624**
EXAMINER: **BALASUBRAMANIAN, VENKATARAMAN**

APPLICATION NO: **10/678388**
FILED: **10/03/2003**
FOR: **HETEROARYL-SUBSTITUTED PYRROLO-TRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS**

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed concurrently with the Petition for Revival of an Application for Patent Abandoned Unintentionally. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Copies of the references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Joseph C. Wang
Attorney for Applicant
Reg. No. 44,391
Phone: 609-252-4931

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Date: July 12, 2006

PTO/SB/08B (6/03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

COMPLETE IF KNOWN	
Application Number	10/678388
Filing Date	10/03/2003
First Named Inventor	KATERINA LEFTHERIS
Art Unit	1624
Examiner Name	BALASUBRAMANIAN, VENKATARAMAN
Attorney Docket Number	QA0267B - CIP

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s). publisher, city and/or country where published	Check box if English language Translation is attached
		Branger, J., et al., "Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia", The Journal of Immunology, Vol. 168, pp. 4070-4077, (2002)	
		Davis, J. C., Jr., "Understanding the Role of Tumor Necrosis Factor Inhibition in Ankylosing Spondylitis", Seminars in Arthritis and Rheumatism, Vol. 34, pp. 668-677, (2004)	
		Gottlieb, A. B., et al., "TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques[1], The Journal of Immunology, Vol. 175, pp. 2721-2729, (2005)	
		Hideshima, T. et al, "Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu", Blood, Vol. 101(2), pp. 703-706, (2003)	
		Johansen, C., et al., "Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 2[1]", The Journal of Immunology, Vol. 176, pp. 1431-1438, (2006)	
		Johansen, C., et al., "The mitogen-activated protein kinases p38 and KRK1/2 are increased in lesional psoriatic skin", British Journal of Dermatology, Vol. 152, pp. 37-42, (2005)	
		Kumar, S., et al., "P38 MAP Kinases: Key Signalling Molecules as Therapeutic Targets for Inflammatory Diseases", Vol. 2, pp. 717-726, (2003)	
		Mease, P. J., et al., "Psoriatic arthritis treatment: biological response modifiers", Ann. Rheum. Dis., Vol. 64 (Suppl. II), pp. ii78-ii82, (2005)	
		Navas, TA, et al., "Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X_L, MCl-1 and p53 levels *in vitro* and inhibits tumor growth *in vivo*, Leukemia, 1-11 (2006)	
		Papp. K. A., "The long-term efficacy and safety of new biological therapies for psoriasis", Arch. Dermatol. Res. Vol. 298, pp. 7-15, (2006)	
		Saklatvala, J., "The p38 MAP kinase pathway as a therapeutic target in inflammatory disease", Current Opinion in Pharmacology, Vol. 4, pp. 372-377, (2004)	
		Waetzig G. H., "p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel Disease[1]", The Journal of Immunology, Vol. 168, pp. 5342-5351, (2002)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant